Eberhard Standl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6543241/publications.pdf

Version: 2024-02-01

60	11,202	159525	102432
papers	citations	30 h-index	66 g-index

71	71	71	9732
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, The, 2005, 366, 1279-1289.	6.3	3,840
2	Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 232-242.	13.9	2,188
3	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2006, 28, 88-136.	1.0	1,144
4	The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart. European Heart Journal, 2004, 25, 1880-1890.	1.0	532
5	Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply. European Heart Journal, 2007, 28, 1402-1402.	1.0	392
6	Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. European Journal of Preventive Cardiology, 2019, 26, 25-32.	0.8	365
7	Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease. Diabetes Care, 2007, 30, 2773-2778.	4.3	266
8	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	5.5	245
9	Therapeutic potential of Î±-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opinion on Pharmacotherapy, 2015, 16, 1959-1981.	0.9	218
10	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126.	3.0	196
11	The global epidemics of diabetes in the 21st century: Current situation and perspectives. European Journal of Preventive Cardiology, 2019, 26, 7-14.	0.8	195
12	Postprandial Hyperglycemia and Glycemic Variability. Diabetes Care, 2011, 34, S120-S127.	4.3	148
13	Alpha-glucosidase inhibitors 2012 â€“ cardiovascular considerations and trial evaluation. Diabetes and Vascular Disease Research, 2012, 9, 163-169.	0.9	115
14	Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. European Heart Journal, 2007, 29, 177-184.	1.0	99
15	The 12-Month Efficacy and Safety of Insulin Detemir and NPH Insulin in Basal-Bolus Therapy for the Treatment of Type 1 Diabetes. Diabetes Technology and Therapeutics, 2004, 6, 579-588.	2.4	84
16	Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era. Diabetes Care, 2020, 43, 1427-1432.	4.3	72
17	Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care, 2017, 40, 1763-1770.	4.3	60
18	Current perspectives on cardiovascular outcome trials in diabetes. Cardiovascular Diabetology, 2016, 15, 139.	2.7	59

#	Article	IF	Citations
19	Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. Diabetes Care, 2018, 41, 596-603.	4.3	59
20	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2017, 5, 391-402.	5.5	56
21	Defending the Con Side: Obesity Paradox Does Not Exist. Diabetes Care, 2013, 36, S282-S286.	4.3	54
22	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. Circulation Research, 2016, 118, 1830-1843.	2.0	51
23	Updates on cardiovascular outcome trials in diabetes. Cardiovascular Diabetology, 2017, 16, 128.	2.7	45
24	On the potential of acarbose to reduce cardiovascular disease. Cardiovascular Diabetology, 2014, 13, 81.	2.7	42
25	Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 353.	0.4	40
26	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care, 2020, 43, 643-652.	4.3	38
27	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovascular Diabetology, 2021, 20, 218.	2.7	38
28	Good Glycemic Control With Flexibility in Timing of Basal Insulin Supply: A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care, 2005, 28, 419-420.	4.3	36
29	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. European Heart Journal, 2019, 40, 2907-2919.	1.0	32
30	New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?. Diabetes Care, 2016, 39, S172-S179.	4.3	27
31	Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose Tolerance. Circulation: Heart Failure, 2013, 6, 203-210.	1.6	26
32	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2012, 2, e001925.	0.8	23
33	DPP-4 inhibitors and risk of heart failure EXAMINEd. Lancet, The, 2015, 385, 2022-2024.	6.3	21
34	Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the <scp>TECOS</scp> randomized clinical trial. European Journal of Heart Failure, 2020, 22, 2026-2034.	2.9	18
35	Heart failure outcomes and Covid-19. Diabetes Research and Clinical Practice, 2021, 175, 108794.	1.1	18
36	The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. Journal of Diabetes and Its Complications, 2011, 25, 202-207.	1.2	17

#	Article	IF	Citations
37	The impact of glucose-lowering therapy on cardiovascular outcomes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 401-411.	2.2	14
38	Dysglycemia and Abdominal Obesity. Current Vascular Pharmacology, 2012, 10, 678-679.	0.8	13
39	What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons. Diabetes/Metabolism Research and Reviews, 2012, 28, 60-66.	1.7	13
40	Targets for blood glucose: What have the trials told us. European Journal of Preventive Cardiology, 2019, 26, 64-72.	0.8	13
41	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. Hypertension, 2017, 70, 907-914.	1.3	12
42	On the prognostic value of post-load glucose in patients with coronary artery disease. European Heart Journal, 2018, 39, 2746-2748.	1.0	10
43	Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. Diabetes Research and Clinical Practice, 2020, 161, 108054.	1.1	10
44	GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis. Lancet Diabetes and Endocrinology,the, 2019, 7, 741-743.	5.5	9
45	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovascular Diabetology, 2021, 20, 75.	2.7	9
46	Predictors of Stroke in Patients With Impaired Glucose Tolerance. Stroke, 2013, 44, 2590-2593.	1.0	8
47	Hypoglycaemia and its management in primary care setting. Diabetes/Metabolism Research and Reviews, 2020, 36, e3332.	1.7	8
48	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovascular Diabetology, 2022, 21, 50.	2.7	8
49	Statins and beyond: Concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes. Diabetes and Vascular Disease Research, 2013, 10, 99-114.	0.9	7
50	Insulin as a First-Line Therapy in Type 2 Diabetes: Should the use of sulfonylureas be halted?. Diabetes Care, 2008, 31, S136-S139.	4.3	6
51	Does using HbA1c inform diagnosis of diabetes in patients with coronary artery disease?: FigureÂ1. European Heart Journal, 2015, 36, 1149-1151.	1.0	6
52	Corrections needed to 2016 ESC guideline and AHA scientific statement on heart failure. Lancet Diabetes and Endocrinology,the, 2017, 5, 325-326.	5.5	6
53	Metformin in type 1 diabetes. Lancet Diabetes and Endocrinology,the, 2017, 5, 567-569.	5.5	5
54	Glycemic Control: A Combination of Lifestyle Management and the Use of Drugs. Cardiology and Therapy, 2013, 2, 1-16.	1.1	4

#	Article	IF	Citations
55	Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Research and Clinical Practice, 2021, 177, 108870.	1.1	4
56	Guideline Development for Medical Device Technology: Issues for Consideration. Journal of Diabetes Science and Technology, 2023, 17, 1698-1710.	1.3	2
57	Diabetes and cardiovascular disease. Clinical Research in Cardiology Supplements, 2010, 5, 27-34.	2.0	1
58	Heart failure in diabetes: From an increased risk to a treatment target. Diabetes Mellitus, 2018, 21, 399-403.	0.5	1
59	Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157â€“163. Diabetes Care, 2019, 42, e95-e95.	4.3	0
60	Heart failure at the crossroads of cardiology and diabetology. Diabetes Research and Clinical Practice, 2021, 175, 108844.	1.1	0